LL-37 Reconstitution & BAC Water Research Guide
LL-37 is the 37-residue human cathelicidin-derived antimicrobial peptide studied for innate immune defense, antimicrobial activity, inflammatory signaling, and tissue-repair biology. There is no single scientifically established BAC-water volume that applies to every LL-37 research vial; the required liquid volume depends on the vial's actual peptide quantity and the target research concentration.
LL-37 Research Snapshot
How Much BAC Water for LL-37?
There is no single universal BAC-water volume for LL-37. The correct mathematical concentration depends on the total quantity of peptide in the vial and the final liquid volume. The same vial can therefore produce different concentrations when different liquid volumes are used.
For example, if a hypothetical research vial contains 5 mg of LL-37:
- 5 mg ÷ 1 mL = 5 mg/mL
- 5 mg ÷ 2 mL = 2.5 mg/mL
- 5 mg ÷ 2.5 mL = 2 mg/mL
- 5 mg ÷ 5 mL = 1 mg/mL
These are mathematical examples only. They do not establish a preferred LL-37 concentration, recommended vial size, clinical dose, or universal BAC-water instruction.
Mathematical LL-37 Concentration Examples
Because no universal LL-37 research-vial quantity should be assumed, the table below uses hypothetical vial quantities to demonstrate the concentration relationship.
| Hypothetical LL-37 Vial | 1 mL | 2 mL | 2.5 mL | 3 mL | 5 mL |
|---|---|---|---|---|---|
| 1 mg | 1 mg/mL | 0.5 mg/mL | 0.4 mg/mL | 0.33 mg/mL | 0.2 mg/mL |
| 5 mg | 5 mg/mL | 2.5 mg/mL | 2 mg/mL | 1.67 mg/mL | 1 mg/mL |
| 10 mg | 10 mg/mL | 5 mg/mL | 4 mg/mL | 3.33 mg/mL | 2 mg/mL |
Need a different LL-37 vial quantity or liquid volume?
Use the BacScience BAC Water Calculator to calculate concentration from your own vial quantity and selected volume.
How Much BAC Water Should Be Added to a Vial of LL-37?
Scientifically, the answer cannot be reduced to one universal number. First identify the actual amount of LL-37 in the vial, then determine the target concentration for the particular research protocol. The required liquid volume follows from the concentration equation.
How Much BAC Water for 5 mg of LL-37?
For a hypothetical 5 mg LL-37 vial, the mathematical concentration would be 5 mg/mL with 1 mL of liquid, 2.5 mg/mL with 2 mL, 2 mg/mL with 2.5 mL, 1.67 mg/mL with 3 mL, and 1 mg/mL with 5 mL.
These calculations do not establish that any of those volumes is appropriate for a particular product or experimental protocol.
How Much BAC Water for 10 mg of LL-37?
For a hypothetical 10 mg vial, 1 mL gives 10 mg/mL mathematically, 2 mL gives 5 mg/mL, 2.5 mL gives 4 mg/mL, 3 mL gives approximately 3.33 mg/mL, and 5 mL gives 2 mg/mL.
How Does BAC-Water Volume Change LL-37 Concentration?
Holding the total LL-37 quantity constant, increasing liquid volume decreases concentration. Decreasing liquid volume increases concentration. The total amount of peptide represented by the vial does not change merely because the liquid volume changes.
What Is LL-37?
LL-37 is a 37-amino-acid peptide derived from the human cathelicidin precursor protein hCAP18/CAMP. It is the best-characterized human member of the cathelicidin family of antimicrobial peptides.
LL-37 is described in the scientific literature as an amphipathic, cationic peptide with broad antimicrobial activity. It is produced in multiple epithelial and immune-cell contexts and participates in innate host defense.
Why Is LL-37 Scientifically Interesting?
- Direct antimicrobial activity against multiple microorganisms.
- Interaction with microbial membranes.
- Binding and neutralization of bacterial endotoxin such as LPS.
- Immune-cell chemotaxis and immune modulation.
- Research into epithelial repair and wound biology.
- Investigation as a platform for antimicrobial-peptide design.
How LL-37 Works
LL-37 does not have one single biological action. Research describes direct antimicrobial effects together with multiple interactions with host cells and inflammatory signaling pathways.
At the microbial interface, LL-37 can interact with negatively charged membranes and contribute to membrane disruption. Its biological activity is not limited to direct microbial killing: published research also describes interactions with lipopolysaccharide, immune-cell recruitment, inflammatory signaling, and epithelial responses.
What Is LL-37 Being Studied For?
Human Clinical Research
LL-37 has progressed beyond purely laboratory research. Human studies have examined topical LL-37 formulations, particularly in wound-healing research. However, clinical evidence is mixed and does not establish a generally accepted therapeutic use.
Doses & Concentrations Studied in Published Research
The following table summarizes selected human research. The reported concentrations are included for scientific context only and are not BacScience dosage recommendations.
| Study | Population | Concentration / Dose Studied | Route | Frequency | Duration | Key Finding |
|---|---|---|---|---|---|---|
| Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers | 34 participants with venous leg ulcers | 0.5, 1.6, or 3.2 mg/mL | Topical | Twice weekly | 4-week treatment phase | Lower concentration groups showed favorable healing-related outcomes; the study was an early clinical investigation. |
| HEAL LL-37 phase IIb trial | 148 patients with hard-to-heal venous leg ulcers | 0.5 or 1.6 mg/mL | Topical | Study-specific topical administration | Clinical trial protocol | Full-population efficacy analysis did not identify significant improvement in healing versus placebo. |
| LL-37 cream research in diabetic foot ulcers | Planned randomized clinical study | 0.5 mg/mL | Topical cream | Twice weekly | 4 weeks | Investigated LL-37 alongside standard wound care for ulcer healing and bacterial-colonization outcomes. |
Published concentrations and trial parameters should not be converted into self-administration instructions. Different formulations, routes, patient populations, endpoints, peptide preparations, and study designs can produce materially different results.
Preclinical Research
Antimicrobial & Membrane Research
In vitro research has characterized LL-37 as a cationic amphipathic peptide capable of interacting with microbial membranes. This work has helped researchers investigate how peptide charge, structure, membrane composition, and aggregation influence antimicrobial activity.
Immune & Inflammatory Biology
Experimental research also describes LL-37 interactions with immune receptors, chemotactic pathways, endotoxin, cytokines, and inflammatory signaling. These activities can be beneficial or detrimental depending on concentration, tissue, disease context, and biological environment.
Wound & Tissue Research
Laboratory and animal research has investigated LL-37 in epithelial repair, cell migration, angiogenesis, and wound biology. These findings are mechanistic evidence and should not be treated as proof of human clinical effectiveness.
Peptide Engineering
LL-37 has also been used as a template for designing modified antimicrobial peptides intended to improve stability, selectivity, antimicrobial activity, or resistance to proteolysis.
LL-37 Research Reconstitution & Concentration
Reconstitution mathematics is independent of whether a research protocol uses 1 mg, 5 mg, 10 mg, or another quantity. The fundamental calculation is:
Worked Example: 5 mg LL-37
Suppose a hypothetical vial contains exactly 5 mg of LL-37.
| Liquid Volume | Mathematical Concentration |
|---|---|
| 1 mL | 5 mg/mL |
| 2 mL | 2.5 mg/mL |
| 2.5 mL | 2 mg/mL |
| 3 mL | 1.67 mg/mL |
| 5 mL | 1 mg/mL |
BAC Water vs. LL-37 Concentration
Bacteriostatic water is a type of diluent, but the existence of a bacteriostatic diluent does not by itself establish that it is the universally appropriate diluent for every LL-37 preparation or research protocol.
What Changes?
- Final liquid volume.
- Resulting concentration.
- Amount of peptide per milliliter.
- Physical characteristics of the resulting formulation.
What Does Not Change Mathematically?
- Total LL-37 quantity originally present in the vial.
- The mass of peptide represented by the vial.
- The concentration equation itself.
Research Limitations & Safety
Why LL-37 Research Is Difficult to Generalize
- LL-37 has multiple biological activities rather than a single target.
- Effects can differ according to concentration, tissue, formulation, route, and biological environment.
- Some experimental concentrations can affect mammalian cell viability, particularly at higher concentrations in vitro.
- Human clinical studies have not produced a simple universal efficacy conclusion.
- Peptide purity, aggregation, degradation, impurities, and formulation can influence experimental outcomes.
- A published research concentration is not automatically an appropriate concentration for another LL-37 preparation.
Concentration vs. Dose vs. Regulatory Status
| Term | Meaning | What It Does NOT Mean |
|---|---|---|
| Mathematical concentration | Amount of LL-37 per unit volume, such as mg/mL. | It is not a clinical dose. |
| Experimental concentration | Concentration used in a specific laboratory or clinical research protocol. | It is not automatically suitable for another experiment. |
| Clinical dose | A protocol-specific amount administered to research participants. | It is not a universal recommendation. |
| FDA-approved dosage | A dosing regimen associated with an FDA-approved drug product and indication. | LL-37 does not have an FDA-approved drug dosage established by this page. |
| Community protocol | Anecdotal or non-authoritative usage information. | It is not evidence of safety, efficacy, or regulatory approval. |
Frequently Asked Questions About LL-37
How much BAC water should be added to LL-37?
There is no universal LL-37 BAC-water volume established by the authoritative sources reviewed. The mathematical volume depends on the actual peptide quantity and the target concentration for the specific research protocol.
How much BAC water for 5 mg of LL-37?
Mathematically, 5 mg in 1 mL produces 5 mg/mL; 2 mL produces 2.5 mg/mL; 2.5 mL produces 2 mg/mL; 3 mL produces approximately 1.67 mg/mL; and 5 mL produces 1 mg/mL. These are calculations, not reconstitution recommendations.
How much BAC water for 10 mg of LL-37?
Mathematically, 10 mg in 1 mL produces 10 mg/mL; 2 mL produces 5 mg/mL; 2.5 mL produces 4 mg/mL; 3 mL produces approximately 3.33 mg/mL; and 5 mL produces 2 mg/mL.
What is the formula for calculating LL-37 concentration?
Concentration in mg/mL equals the total LL-37 quantity in milligrams divided by the liquid volume in milliliters: mg ÷ mL = mg/mL.
Does adding more BAC water lower LL-37 concentration?
Yes. If the total amount of LL-37 stays constant, increasing the liquid volume decreases the resulting concentration.
Is LL-37 an FDA-approved drug?
No FDA-approved LL-37 drug product or FDA-approved LL-37 dosage is established by this page. FDA has evaluated compounded LL-37 in the context of potential safety risks and identified important uncertainties.
Has LL-37 been studied in humans?
Yes. Human studies have investigated LL-37, including topical formulations in clinical wound-healing research. Results have not established a universally accepted therapeutic use.
What LL-37 concentration was studied in venous leg ulcers?
One randomized clinical study investigated topical LL-37 at 0.5, 1.6, and 3.2 mg/mL. A later phase IIb study investigated 0.5 and 1.6 mg/mL. These were study-specific formulations and should not be interpreted as universal recommendations.
Is a published LL-37 research concentration a recommended concentration?
No. A published concentration describes the conditions of a specific study. It does not establish a universal concentration for every LL-37 product or research application.
Does BacScience recommend a human LL-37 dose?
No. BacScience's educational concentration information should not be interpreted as a human dosing recommendation or treatment protocol.
Can the BAC Water Calculator calculate a custom LL-37 concentration?
Yes. The mathematical calculation can be performed using the actual vial quantity and selected liquid volume. The calculator does not determine a medically appropriate dose or validate a particular product formulation.
Is BAC water automatically appropriate for every LL-37 preparation?
No. Diluent compatibility, formulation, sterility, stability, preservative compatibility, and intended experimental use should be established from appropriate product or laboratory documentation.
Related BacScience Research Resources
Scientific References
- Dürr UNH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006. PMID: 16716248.
- Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cellular Immunology. 2012. PMID: 23246832.
- Ridyard KE, Overhage J. The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent. Antibiotics. 2021. PMID: 34072318.
- Svensson D, Nilsson BO. Human antimicrobial/host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: an update. Inflammation Research. 2025. PMID: 40063262.
- Koczulla R et al. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. PMID: 25041740.
- Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial. Phase IIb human clinical research. PMID: 34687253.
- ClinicalTrials.gov. NCT04098562 — The Efficacy of LL-37 Cream on Bacteria Colonization, Inflammation Response and Healing Rate of Diabetic Foot Ulcers.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA regulatory information concerning compounded cathelicidin LL-37.
Scientific review based on FDA regulatory information, PubMed-indexed literature, and ClinicalTrials.gov records. Scientific Reviewer: [INSERT QUALIFIED SCIENTIFIC REVIEWER].